Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Phargentis AB
AB
Active
Org 5593400467
Älvsåkersgränd 46, 125 72
Älvsjö
Manufacture of pharmaceutical preparations
·
NACE 2120
Est. 2021 · 4 years old
0 employees
Monitor
Share
Sweden
/
Companies
/
Manufacture of pharmaceutical preparations
/
Phargentis AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
0M
2024
EBITDA
SEK millions
0M
-1M
-3M
-4M
-5M
-1M
2021
-4M
-300%
2022
-3M
+25%
2023
-1M
+67%
2024
Income statement
SEK thousands
Item
2021
2022
2023
2024
Revenue
0
0
0
229
Staff expenses
—
—
—
—
EBITDA
−1 123
−3 821
−2 565
−689
Depreciation & amort.
−0
−0
−0
−0
EBIT
−1 123
−3 821
−2 565
−689
Net financials
—
530
1 407
−68 749
Profit before tax
−1 123
−3 291
−1 158
−69 438
Tax
−0
−0
−0
−0
Net profit
−1 123
−3 291
−1 158
−69 438
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
Total assets
3 277
83 623
82 854
12 997
Equity
1 902
82 627
81 469
12 031
Long-term debt
0
0
0
0
Short-term debt
1 375
996
1 385
966
Total debt
1 375
996
1 385
966
Financial ratios
5-year trend
EBITDA margin
-300.9%
This company
15.8%
Market median
-2004% vs market
2021
2024
Equity ratio
92.6%
This company
38.2%
Market median
+142% vs market
2021
2024
Return on equity
-577.2%
This company
18.4%
Market median
-3237% vs market
2021
2024
Net profit margin
-30322.3%
This company
8.1%
Market median
-374449% vs market
2021
2024
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
2021
2024
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
2021
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-10-01 – 2021-12-31
View
PDF
More on Phargentis AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
